Curtis D. Chin

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial”.

Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial

Nature Communications(2025)10.1038/s41467-024-55642-8

N/A

0.406DataRank · unranked

12 citations

Herbert Yu, Ying Yuan, Jianfeng Chen, Xinmiao Yan, Menuka Karki +22 more

Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma

Nature Communications(2023)10.1038/s41467-023-38342-7

N/A

0DataRank · unranked

49 citations

Pavlos Msaouel, Cara Haymaker, Surena F. Matin, Matthew T. Campbell, Amado J. Zurita +17 more